Pediatric Dovato: EMA Approves Application for HIV Therapy https://ymaho.com/pediatric-dovato-ema-approves-application-for-hiv-therapy
EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.
EMA accepted the application for Dovato for children with HIV https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv
EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.
Pediatric Dovato: ViiV application and geopolitics of the HIV market https://ymaho.com/pediatric-dovato-viiv-application-and-geopolitics-of-the-hiv-market
ViiV has submitted applications to the FDA and EMA for dispersible Dovato tablets for children. We analyze the strategy, patents, and implications. Find out who will win.
Study of the Ottava robot: FORTE results and FDA application https://ymaho.com/study-of-the-ottava-robot-forte-results-and-fda-application
Scientists have completed the pivotal study of the Ottava robot (FORTE) and are preparing an FDA application. Learn about clinical data, zero conversions, and market prospects for robotic surgery.
Gene therapy for deafness otarmeni EMA: accelerated review 2026 https://ymaho.com/gene-therapy-for-deafness-otarmeni-ema-accelerated-review-2026
EMA accepted the application for gene therapy otarmeni for the treatment of hereditary deafness OTOF. Market analysis, forecasts, price and implications for the industry. Read.
SpaceX IPO: filing for $75 billion and valuation of $1.75 trillion https://ymaho.com/spacex-ipo-filing-for-75-billion-and-valuation-of-1-75-trillion
SpaceX filed an application for the largest IPO in history on Nasdaq up to $75 billion. Valuation $1.75 trillion, listing in June 2026. Analysis of the record, consequences and hidden details. Read more.
Intellia CRISPR therapy: FDA filing for lonvo-z for HAE https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae
Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.
Linlithgow Rose SPFL Play-Off Exclusion Due to Licence https://lrivo.com/linlithgow-rose-spfl-play-off-exclusion-due-to-licence
Linlithgow Rose miss SPFL play-offs after SFA bronze licence application declined. Brora Rangers face Edinburgh City in final. Learn why.
AI for early diagnosis of gallbladder cancer: accuracy 92-97% https://ymaho.com/ai-for-early-diagnosis-of-gallbladder-cancer-accuracy-92-97
PGIMER AI model analyzes ultrasound and detects gallbladder cancer at an early stage. Free application for hospitals. Data from The Lancet. Learn more.
IPO of UzNIF: Uzbekistan's entry onto the London Stock Exchange for $1.95 billion https://ymaho.com/ipo-of-uznif-uzbekistan-s-entry-onto-the-london-stock-exchange-for-1-95-billion
Dual IPO of Uzbekistan's National Fund for $1.95 billion in Tashkent and London. GDR price — $25. Submit your application by May 12 and learn the placement details.